Ranbaxy Laboratories on Monday launched the first biosimilar version of Johnson and Johnson’s Remicade, a drug used for treating various conditions including rheumatoid arthritis. Infimab has been introduced in the domestic market through a licensing partnership with Epirus Biopharmaceuticals, Ranbaxy said in a statement. Infimab will be manufactured by Reliance Life Sciences at its facility in Mumbai, it added.